(May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought. In fact, it may be affected by effector T cells (cells that defend the body in an immune response) in the tumor microenvironment. Thus, a combination of platinum-based chemotherapies and immunotherapy could be a promising approach to treating cancer. The results were published recently in Cell.
Read the abstract. and learn more about Dr. Zou’s research.
Read more about this study in News Medical.
